Browsing by Author Cortés, Javier

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)
2018-11-02A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.
2018A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
2017-11Advances in the management of HER2-positive early breast cancer.Baselga, José; Coleman, Robert E; Cortés, Javier; Janni, Wolfgang
2017Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
2018-09-11CXCR4 antagonists for treatment of breast cancer.Cortés, Javier; Holgado, Esther; Perez-Garcia, Jose
2020Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
2017Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
2018Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
2015-11-10MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
2017-09-01MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
2018Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
2018Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
2017-09Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
2016Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
2016Translating neoadjuvant therapy into survival benefits: one size does not fit all.De Mattos-Arruda, Leticia; Shen, Ronglai; Reis-Filho, Jorge S; Cortés, Javier